Phase 3 Cardiomyopathy Trial, Recruiting NCT06563895 Sponsor: Eidos Therapeutics, a BridgeBio company Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 3 Cardiomyopathy Trial, Recruiting

NCT06563895
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (inclusive)
  • You have had a genetic test (for medical reasons) that confirmed you carry a gene change in the TTR gene that is known or likely to cause disease (for example, variants called V30M, V122I, T60A, or others)
  • Your age is within 10 years (younger or older) of a specific reference age related to the study design (confirm with trial site)

Who may not be able to join:

  • You already have signs or symptoms of TTR-related heart disease or nerve disease
  • You are currently taking, or have recently taken (within the past 1 to 12 months, depending on the medication), other treatments that affect the TTR protein
  • You are unable to have a cardiac MRI scan (a special heart imaging test), or there is a medical reason you should not have one
  • You have a major problem with an organ such as your kidneys, liver, heart, or nervous system
  • You have had cancer in the past 5 years, an untreated thyroid problem, type 1 diabetes, active hepatitis B or C, or HIV
  • You have had major surgery in the last 3 months, or are planning to have major surgery in the next 12 months
  • You have had a known allergic reaction to the study drug, acoramidis

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-844-550-2246

Australian sites

St Vincent's Hospital Sydney, Darlinghurst,
Fiona Stanley Hospital, Murdoch,
Westmead Hospital, Westmead,
Princess Alexandra Hospital, Woolloongabba,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Eidos Therapeutics, a BridgeBio company
Registry
ClinicalTrials.gov
Start date
12 May 2025
Est. completion
1 October 2031

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇬🇷 Greece 🇮🇪 Ireland 🇮🇹 Italy 🇯🇵 Japan 🇲🇾 Malaysia Martinique 🇲🇽 Mexico 🇳🇱 Netherlands 🇵🇹 Portugal 🇸🇬 Singapore 🇰🇷 South Korea 🇪🇸 Spain 🇸🇪 Sweden 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time to development of ATTR (ATTR-CM or ATTR-PN, whichever occurs first; centrally adjudicated)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov